2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2962 Single-cell RNA sequencing defines the immune response to PRMT5 inhibition in a mouse model of secondary HLH

Paola Marra, Rosario Distefano2, Ian Hout3, Atashi Sharma, PhD4, Xi Chen, PhD5, Robert A Baiocchi, MD, PhD6, Polina Shindiapina, MD, PhD7
1 Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio, United States
2 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States
3 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States
4 Genomic Shared Resource, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio, United States
5 Genomic Shared Resource, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio, United States
6 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States
7 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States

Introduction. Secondary hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory disorder associated with uncontrolled immune-activation, excessive release of proinflammatory cytokines, and substantial mortality. Protein arginine methyltransferase 5 (PRMT5) is an enzyme that regulates gene transcription and protein signaling through symmetric arginine dimethylation. PRMT5 has been implicated in immune-cell activation and regulation of inflammation. In this study, we investigated how pharmacologic inhibition of PRMT5 alters pathogenic immune-cell populations and inflammatory transcriptional programs involved in HLH progression.

Methods. Secondary HLH was established in C57BL/6 mice through repeated intraperitoneal injections of CpG 1826 and anti-IL-10 receptor antibody. Animals were randomly assigned to three experimental groups: healthy control, HLH mice receiving vehicle, and HLH mice treated with the PRMT5 inhibitor PRT382 at 1 mg/kg once a day, beginning on day 4. Mice were euthanized on day 8, and spleens were processed for scRNA-seq using the 10x Genomics Flex v1 kit. Data were analyzed with Scanpy v1.12.1 and R v4.5.3. After sample-level QC and filtering, high-quality cells were log-normalized with scran v1.30.0 and integrated using Harmony v2.0, followed by nearest-neighbor graph construction, Leiden clustering, and UMAP visualization. Cellular populations were manually annotated based on canonical markers, expression levels, and the proportion of expressing cells. Pseudobulk counts generated with decoupleR v2.16 were analyzed with DESeq2 v1.52.0 for DGE analysis. Genes ranked by Wald statistic were then used for GSEA with GSEApy v1.1.12.

Results. Single-cell transcriptomic analysis revealed that PRMT5 inhibition primarily attenuated inflammatory cytokine programs within the lymphoid compartment. HLH is marked by increased production of inflammatory cytokines (IL-1β, IL-2, IFNγ, TNFα, IL-12, IL-15, IL-18). In vehicle-treated HLH mice, increased Ifng expression extended across several activated lymphocyte populations, including Cd8+ T cells, regulatory T cells, memory Cd4+ T cells, and NKT. Il2 expression was elevated in naïve Cd8+ T cells, NK cells, and NKT cells. Tnf showed a broader distribution, appearing across naïve Cd4+ and Cd8+ T cells, regulatory T cells, and γd T cells. Treatment with PRT382 consistently dampened expression of these cytokines across their respective populations, supporting the hypothesis that PRMT5 inhibition suppresses cytokine-producing lymphocytes in secondary HLH. The reduction in lymphoid cytokine expression was accompanied by attenuation of the metabolic activation state observed in vehicle-treated cells. Ifng-expressing T cells exhibited enrichment in PI3K-AKT-mTOR signaling, glycolysis, oxidative phosphorylation, and cholesterol homeostasis programs, all of which were reduced following PRT382 treatment. These findings suggest that PRMT5 inhibition limits the metabolic program that sustains lymphocyte activation and inflammatory cytokine expression. Although Tnf expression decreased in neutrophils, monocytes, and macrophages, the expression of Il12, Il15, and Il18 persisted across multiple myeloid populations despite PRT382 administration. Maintenance of these cytokine signals suggests that NK cell may remain stimulated by myeloid-derived activating cytokines despite PRMT5 inhibition. Similarly, Il1b expression was not substantially reduced by PRT382, providing a rationale for future evaluation of combined PRMT5 inhibition and IL-1 blockade as a therapeutic strategy. Despite the persistence of these myeloid-derived cytokines, PRT382 reduced pathways associated with inflammatory amplification, tissue damage, and cytotoxicity in myeloid cells. Macrophages in PRT382-treated mice showed reduced pathways associated with mTORC signaling, regulation of type I and type II interferon production, TNFasignaling through NF-kB, and IFNγ response. Thus, while PRMT5 inhibition did not broadly eliminate myeloid cytokine expression, it shifted macrophages away from an interferon-responsive and tissue-damaging inflammatory state.

Conclusions. In a mouse model of secondary HLH, PRMT5 inhibition preferentially restrains metabolically activated, cytokine-producing lymphocytes while limiting tissue-damaging myeloid responses, thereby disrupting pathogenic lymphoid-myeloid communication and supporting combination cytokine-targeted therapy.

PM and RD contributed equally to this work.

Paola Marra: No relevant conflicts of interest to declare.